Allogene Therapeutics, Inc. - ALLO STOCK NEWS

Allogene Therapeutics (Nasdaq: ALLO) recently showcased promising preclinical data on a one-step gene editing strategy designed to prevent the rejection of AlloCAR T™ cells by host immune cells. This approach demonstrated its superiority over B2M knockout in a syngeneic in vivo model. The proprietary technology aims to enhance the effectiveness of off-the-shelf CAR T therapies by cloaking these cells from both T and NK cells. This research was presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer.

Allogene Therapeutics (Nasdaq: ALLO) will host a Research & Development Showcase on November 29, 2022, to discuss its CD19 and BCMA programs. The hybrid event will occur at 10:00 AM PT in New York, with limited in-person attendance. Registration is required. Additionally, Allogene will participate in five investor conferences starting with the Cowen 6th Annual IO Next Summit on November 11, 2022. Webcasts will be available on the company’s website for those unable to attend.

Allogene Therapeutics announced promising results from its Phase 1 UNIVERSAL trial of ALLO-715, an allogeneic CAR T product for multiple myeloma, demonstrating significant responses. The updated data, including safety and efficacy results from lymphodepletion, will be presented at the American Society of Hematology meeting from December 10-13, 2022. The company will also host a Research & Development Showcase on November 29, 2022, to discuss further plans and insights regarding ALLO-715.

Allogene Therapeutics (Nasdaq: ALLO) has initiated the ALPHA2 trial, the first allogeneic CAR T Phase 2 trial aimed at treating relapsed/refractory large B-cell lymphoma. This single-dose trial employs 120 million CAR+ cells alongside a lymphodepletion regimen. The company also is preparing for the EXPAND trial, testing the role of ALLO-647 in lymphodepletion. As of Q3 2022, Allogene reported $637 million in cash and a net loss of $83.1 million. Future developments include an R&D showcase on November 29, 2022, to update clinical data from existing programs.

Allogene Overland Biopharm has completed a cutting-edge AlloCAR T manufacturing facility in Shanghai, enabling production for Greater China, Taiwan, South Korea, and Singapore. This milestone supports the accelerated development of AlloCAR T products, addressing the significant need for cell therapies in Asia. The 68,000 square foot GMP facility is designed for scalable and simultaneous production of multiple therapies. The venture aims to enhance access to allogeneic CAR T options and initiate clinical trials for new indications, marking a pivotal step in cancer treatment in the region.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) will report its third quarter 2022 financial results on November 2, 2022, after the market closes. A live audio webcast and conference call will follow at 2:00 PM PT/5:00 PM ET. Investors can access the live event on the company's website, with a replay available for 30 days. Allogene Therapeutics is dedicated to developing allogeneic CAR T cell products for cancer treatments, aiming to provide accessible cell therapy solutions on-demand.

Allogene Therapeutics (ALLO) has launched the CAR T Together initiative to enhance access to allogeneic CAR T therapies for cancer patients. A recent survey showed that only 50% of eligible patients receive current autologous CAR T treatments, with significant delays in access, as 40% wait three to six months. The initiative aims to accelerate clinical trials for 'off-the-shelf' CAR T products, addressing the challenges of patient demand and manufacturing capacity.

Allogene Therapeutics has initiated the Phase 2 ALPHA2 trial for ALLO-501A in relapsed/refractory large B-cell lymphoma patients, aiming to demonstrate the efficacy of a single-dose regimen paired with ALLO-647. Supported by promising Phase 1 data, the trial will enroll around 100 patients, focusing on the objective response rate as its primary endpoint. The company also plans to launch the EXPAND trial to assess the contribution of ALLO-647. The FDA recently granted Regenerative Medicine Advanced Therapy designation to ALLO-501A, underscoring its potential in addressing unmet treatment needs.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a biotechnology company focused on allogeneic CAR T (AlloCAR T™) products for cancer, announced its participation in the Jefferies Cell and Genetic Medicine Summit on September 30, 2022, at 6:30 AM Pacific Time. Management will present insights about its pipeline of 'off-the-shelf' CAR T cell candidates aimed at improving availability and scalability of cell therapy. A live webcast will be available on the company’s website, with a replay accessible for 30 days afterwards.